Gluten in Medicine Disclosure Act of 2021

Bill: 117-hr-2435
Sponsor: full_name: Rep. Ryan, Tim [D-OH-13]
Introduced: 2021-04-08
Policy area: Health
Subjects: Consumer affairs

Drug safety, medical device, and laboratory regulation

Grain

Nutrition and diet

Prescription drugs
Latest action: action_date: 2021-04-09
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2021-04-08
action_desc: Introduced in House
text: <p><b>Gluten in Medicine Disclosure Act of 2021</b></p> <p>This bill prohibits the sale of any drug intended for human use that contains an ingredient derived from a gluten-containing grain unless the drug's label (1)states that the drug contains such an ingredient, and (2)identifies the type of grain from which the ingredient is derived.</p>

tv_txt: I 117th CONGRESS 1st Session H. R. 2435 IN THE HOUSE OF REPRESENTATIVES April 8, 2021 Mr. Ryan (for himself and Mr. Stivers ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Federal Food, Drug, and Cosmetic Act to require the label of a drug that is intended for human use and contains an ingredient that is derived directly or indirectly from a gluten-containing grain to identify each such ingredient, and for other purposes.

1. Short title This Act may be cited as the Gluten in Medicine Disclosure Act of 2021 . 2. Labeling of drugs with an ingredient made from a gluten-containing grain (a) Misbranding Section 502 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 352 ) is amended by adding at the end the following: (gg) If it is a drug— (1) that is intended for human use; (2) that contains an ingredient that is derived directly or indirectly from a gluten-containing grain (including wheat, barley, rye, and their crossbred hybrids); and (3) whose label fails— (A) to state that the drug contains such an ingredient; and (B) to identify each such ingredient and the type of gluten-containing grain from which it is derived. . (b) Applicability Section 502(gg) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a) of this section, shall apply beginning on the sooner of— (1) a date to be determined by the Secretary of Health and Human Services; and (2) the date that is 2 years after the date of the enactment of this Act.